INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Universidad Católica de Valencia San Vicente Mártir
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Universidad Católica de Valencia San Vicente Mártir (19)
2024
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
2023
-
A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
Hematology (United Kingdom), Vol. 28, Núm. 1
-
A reproducible and repeatable digital method for quantifying nasal and sinus airway changes following suture palatine expansion
Sleep and Breathing, Vol. 27, Núm. 3, pp. 1175-1183
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Socio-Emotional Competencies Required by School Counsellors to Manage Disruptive Behaviours in Secondary Schools
Children, Vol. 10, Núm. 2
2022
-
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Cancers, Vol. 14, Núm. 11
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Severity and duration of allergic conjunctivitis: are they associated with severity and duration of allergic rhinitis and asthma?
European Annals of Allergy and Clinical Immunology, Vol. 54, Núm. 6, pp. 277-283
2020
-
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Blood, Vol. 136, Núm. 2, pp. 199-209
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
2017
-
Retos del empleo de la secuenciación masiva de nueva generación (NGS) de la macrofauna bentónica para la evaluación de la calidad ambiental marina
Nereis: revista iberoamericana interdisciplinar de métodos, modelización y simulación, Núm. 9, pp. 81-90
2016
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560
-
Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma
British Journal of Haematology
2015
-
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish/PETHEMA trial
Haematologica, Vol. 100, Núm. 8, pp. 1096-1102
-
Clinical management and use of health care resources in the treatment of nasal polyposis in Spanish allergy centers: The POLAR study
Journal of Investigational Allergology and Clinical Immunology, Vol. 25, Núm. 4, pp. 276-282
-
Consensus document on allergic conjunctivitis (DECA)
Journal of Investigational Allergology and Clinical Immunology, Vol. 25, Núm. 2, pp. 94-106
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
2014
2013
-
Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74